RNA Antisense Abrogation of MAT1 Induces G1 Phase Arrest and Triggers Apoptosis in Aortic Smooth Muscle Cells*

Lingtao WuDagger §, Ping ChenDagger , Jung-Joo Hwang, Lora W. Barskyparallel , Kenneth I. Weinbergparallel , Ambrose Jong**, and Vaughn A. StarnesDagger

From the Divisions of Dagger  Cardiothoracic Surgery, parallel  Research Immunology/BMT, and ** Hematology-Oncology, Childrens Hospital Los Angeles Research Institute, University of Southern California School of Medicine, Los Angeles, California 90027 and the  Department of Biochemistry and Molecular Biology, University of Southern California School of Medicine, Los Angeles, California 90033

    ABSTRACT
Top
Abstract
Introduction
References

The human MAT1 gene (ménage à trois 1) is an assembly factor and a targeting subunit of cyclin-dependent kinase (CDK)-activating kinase. The novel mechanisms by which MAT1 forms an active CDK-activating kinase and determines substrate specificity of CDK7-cyclin H are involved in the cell cycle, DNA repair, and transcription. Hyperplasia of vascular smooth muscle cells (SMC) is a fundamental pathologic feature of luminal narrowing in vascular occlusive diseases, and nothing is yet known regarding the cell cycle phase specificity of the MAT1 gene in its involvement in SMC proliferation. To investigate such novel regulatory pathways, MAT1 expression was abrogated by retrovirus-mediated gene transfer of antisense MAT1 RNA in cultured rat aortic SMCs. We show that abrogation of MAT1 expression retards SMC proliferation and inhibits cell activation from a nonproliferative state. Furthermore, we have demonstrated that these effects are due to G1 phase arrest and apoptotic cell death. Our studies indicate a link between cell cycle control and apoptosis and reveal a potential mechanism for coupling the regulation of MAT1 with G1 exit and prevention of apoptosis.

    INTRODUCTION
Top
Abstract
Introduction
References

The human MAT1 gene (ménage à trois 1) was discovered as the third subunit of cyclin-dependent kinase (CDK)1-activating kinase (CAK) (1-3). CAK exists in either of two forms: (a) the major ternary CAK containing CDK7, cyclin H, and MAT1, which is assembled by MAT1 in the absence of activating phosphorylation of the T-loop of CDK7; and (b) the minor binary CAK lacking MAT1, which requires the phosphorylation of the T-loop of CDK7 for CDK7 binding to cyclin H in the absence of MAT1 (1, 4, 5). MAT1 is associated with both a free form of CAK and a transcription factor IIH (TFIIH)-bound form of CAK (1, 4, 6-10). Up to the present, the known functions of MAT1 have been associated with CAK. CAK was originally implicated in cell cycle control by its ability to phosphorylate and activate CDK1, CDK2, and CDK4 (11-16). Subsequently, CAK was found to associate with TFIIH and to phosphorylate the carboxyl-terminal domain of RNA polymerase II (1, 4, 7-10). TFIIH is required for both initiation of RNA polymerase II-catalyzed transcription and nucleotide excision repair (17-19). Thus, the concept that CAK functions in the regulation of the cell cycle, DNA repair, and transcription has emerged.

Interestingly, all of the functions that link CAK to the cell cycle, DNA repair, and transcription are mediated by MAT1, i.e. MAT1 activation of CAK by stabilizing the association of CDK7 with cyclin H (1, 4, 6) and MAT1 determination of substrate specificity of CAK through (a) switching the substrate preference of CAK to the carboxyl-terminal domain over CDK in the presence of MAT1 (20) and (b) the requirement of MAT1 for efficient phosphorylation of the tumor suppressor protein p53 by CDK7-cyclin H (21). The efficiency of bipartite CDK7-cyclin H in CDK2 phosphorylation is not affected by the addition of MAT1 (20, 21), suggesting that MAT1 more likely acts as a targeting subunit of CAK than significantly influencing CDK7-cyclin H phosphorylation of CDKs. TFIIH lacking the CAK subcomplex completely recovers its transcriptional activity in the presence of free ternary CAK; MAT1 interacts with essential components of the DNA repair machineries XPB (ERCC3) and XPD (ERCC2), which are two helicase subunits of TFIIH that mediate the association of CAK with core TFIIH (10, 22, 23). However, these studies have provided little information about the cell cycle phase specificity and the corresponding regulatory mechanisms of MAT1 itself in the control of cell proliferation.

It is known that the fundamental feature of vascular occlusive disease, including atherosclerosis, hypertension, restenosis, and transplant arteriopathy, is an accumulation of cells and extracellular matrixes in the intima, which consequently results in the narrowing of the vascular lumen. The vascular smooth muscle cell (SMC) represents the cell type most often implicated in the process of luminal narrowing (24-31). In recent years, rapid progress has been made in identifying and understanding the functions of some cell cycle regulators in controlling SMC proliferation. Many important cell cycle factors, including the catalytic subunit CDC2 (32), the negative cell cycle regulator retinoblastoma protein (pRb) (29, 33), and the CDK inhibitor p21 (34), have shown to play important roles in regulating SMC proliferation, even though the molecular mechanisms still remain to be further studied. Considering that eukaryotic cell proliferation is a process that is highly regulated by the ordered assembly and determined substrate specificity of CDKs (35, 36), the functions of MAT1 in assembling and determining substrate specificity of CAK (20, 21) may be directly involved in the regulation of a specific cell cycle phase. Given that MAT1 functions in the cell cycle as an assembly factor and a targeting subunit of CAK, we intended to determine the cell cycle phase specificity of MAT1 functions and the corresponding mechanism of the regulation of SMC proliferation. Our studies show that MAT1 is required for G1 exit. A loss of MAT1 arrests SMCs in G1 phase and induces apoptosis to kill these arrested cells.

    EXPERIMENTAL PROCEDURES

Retroviral Vectors-- An N-terminal 462-bp fragment of the MAT1 gene starting from the 5'-end, 40 bp upstream of the ATG initiation codon and extending to +422 bp of the coding region, was cloned into retroviral vector G1xSvNa (Genetic Therapy Inc./Novartis) in the antisense orientation (G1AsMatSvNa). G1AsMatSvNa indicates the order of the promoter and coding region of the constructs (G1, Moloney murine leukemia virus long terminal repeat sequences; AsMat, antisense MAT1 RNA fragment; Sv, SV40 early enhancer and promoter; Na, neomycin phosphotransferase). The G1AsMatSvNa construct was confirmed by sequencing as described previously (37, 38) using primers complementary to the vector-flanking sequence upstream of the MAT1 antisense fragment and a Sequenase reaction kit (U. S. Biochemical Corp.). G1nBgSvNa bearing a nuclear targeting beta -galactosidase was used for testing gene transfer efficiency.

Production of High Titer Amphotropic Replication-defective Retrovirus-- Retroviral supernatants were prepared as described (39). Briefly, murine amphotropic PA317 packaging cells (American Type Culture Collection) were plated at 20% confluent density (5 × 105 cells) in 100-mm plates with Dulbecco's modified Eagle's medium (Life Technologies, Inc.) containing 10% fetal bovine serum (Hyclone Laboratories) and incubated at 37 °C for 16 h. Cells were transfected with 20 µg of DNA from G1xSvNa, G1AsMatSvNa, or G1nBgSvNa using calcium phosphate precipitation. 12 h after transfection, the cells were washed, and the medium was replaced. After an additional 48-h post-transfection period, cells were split 1:5 and selected with 0.6 mg/ml G418 (Life Technologies, Inc.) for 10 days. The colonies formed by G418-resistant cells were pooled as producer cells, and 4 × 106 cells/175-cm flask were plated for virus production. The supernatants containing amphotropic replication-defective retrovirus were collected after the cells reached 90% confluence and were clarified by centrifugation at 550 × g for 10 min at 4 °C. For determining the viral titer, NIH 3T3 cells were plated at 2.5 × 104 cells/6-well plate and transduced with viral supernatants in the presence of 8 µg/ml Polybrene for 2 h. After a 48-h post-transduction incubation, the cells were selected with 0.6 mg/ml G418 for 10 days. The colonies formed by G418-resistant cells were stained with 0.1% methylene blue (Sigma).

Cells, Retrovirus-mediated Transduction, and Maintenance of Stable Clones-- Rat aortic SMCs (A-10 cell line obtained from American Type Culture Collection) were grown in Dulbecco's modified Eagle's medium supplemented with 15% fetal bovine serum, 200 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin at 37 °C in a 5% CO2 and 95% air atmosphere. The G418 concentration for selection of stable clones was determined by a 7-day lethal dose test. SMCs were plated in 100-mm plates at a 20% confluent density for overnight attachment and transduced with either G1AsMatSvNa (MAT1-AS) or G1xSvNa (vector) at a multiplicity of infection of 10 in the presence of Polybrene (8 µg/ml) for 2 h. After a 48-h post-transduction incubation, the cells were selected for 7 days with 0.25 mg/ml G418. About 20 single stable clones were picked from antisense MAT1-transduced SMCs and expanded for detection of the MAT1 expression phenotype. G418-resistant colonies from G1xSvNa (vector)-transduced SMCs were pooled as a control. Our working model was that G1AsMatSvNa (MAT1-AS)-transduced cells, the MAT1 expression of which has been inhibited, served as a testing sample, whereas G1xSvNa (vector)-transduced cells and additional nontransduced (blank) cells served as controls. The same dose of G418 used for selection was added to the medium for maintenance of stable clones. MAT1 expression in stable clones was tested before and after experiments by Western blotting.

Western Analysis of MAT1 Expression-- Western analysis was performed as described previously (3, 40) with minor modifications. Briefly, cells from G1AsMatSvNa (MAT1-AS)-transduced, G1xSvNa (vector)-transduced, and nontransduced (blank) cultures were grown to <= 80% confluence in 6-well plates. The cells in each well were lysed with 80 µl of lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 25 mM sodium fluoride, 25 mM beta -glycerol phosphate, pH 7.5, 0.1 mM sodium orthovanadate, 0.1 mM phenylmethylsulfonyl fluoride, 5 µg/ml leupeptin, 0.2% (v/v) Triton X-100, and 0.5% (v/v) Nonidet P-40) on ice for 10 min. Cell lysate proteins were centrifuged at 14,000 × g for 15 min at 4 °C. The same amount of protein was denatured in SDS sample buffer at 95 °C for 3 min, separated by electrophoresis on 16% SDS-polyacrylamide gels, and electrophoretically transferred to a polyvinylidene difluoride membrane (Millipore Corp.) in Tris/glycine buffer containing methanol. The MAT1 protein was detected by polyclonal rabbit anti-human MAT1 antibodies (Santa Cruz Biotechnology) and enhanced by chemiluminescence (Western-star, Tropix Inc.) using alkaline phosphatase-conjugated secondary goat anti-rabbit IgG (Sigma) as recommended by the manufacturer. A 40-kDa recombinant His-MAT1 protein expressed from the pET23b construct as described (37) was used as a positive control. The expression level of MAT1 was determined by scanning MAT1 content using a ScanJet IICX/T densitometer (Hewlett-Packard Co.).

Cell Proliferation Analysis-- Cells from G1AsMatSvNa (MAT1-AS)-transduced, G1xSvNa (vector)-transduced, and nontransduced (blank) cultures were used for determining the ratio of cell duplication. The same number of cells were plated in 24-well plates. 24 h after plating, the cells were counted for 3 consecutive days before reaching confluence.

To determine the number of living cells in culture, a cell proliferation assay kit (Promega) was used as recommended by the manufacturer. Briefly, the same number of cells were plated in 96-well plates and cultured for 72 h to <= 90% confluence. Cells were incubated with MTS tetrazolium compound (which is bioreduced to soluble formazan by dehydrogenase enzymes in metabolically active cells) for 1 h at 37 °C. The quantity of the formazan product as measured by the absorbance at 490 nm using a Kinetic Microplate Reader (Molecular Devices) is directly proportional to the number of living cells in culture.

The activation of SMC proliferation from a nonproliferative to proliferative state in an "in vitro injured tissue" was determined as described (41) with minor modifications. Cells were grown in 12-well plates to confluence (when they exhibited contact inhibition) and then scraped with a 200-µl pipette tip to create a 1-mm track devoid of cells in the central area of the wells. The "wound" tracks were immediately washed to remove the detached cells, and fresh medium was added. 24 h after the wound tracks were created, G1nBgSvNa retroviral constructs bearing a nuclear targeting beta -galactosidase were added at a multiplicity of infection of 10 in the presence of Polybrene (8 µg/ml) for 2 h. 48 h post-transduction, gene transfer efficiency was measured by determining the percentage of beta -galactosidase-positive cells upon exposure to 1 ml of staining solution (5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM MgCl2, and 400 µg/ml X-gal (GBT Inc.)). The number of blue cells, which reflected the activation of SMC proliferation and the time for closing the wound track, was assessed under a phase-contrast microscope either at ×40 or ×100 magnification.

Flow Cytometric Analysis of Cell Cycle Status and Apoptosis-- Cell cycle status and cell cycle phase specificity of apoptosis were determined by simultaneously measuring DNA content and DNA breaks as described (42). An APO-DIRECT detection kit (Pharmingen), which works by "tail labeling" dUTP to 3'-OH termini of the DNA breaks by exogenous terminal deoxynucleotidyltransferase and counterstaining integral DNA by propidium iodide, was used following the manufacturer's instructions with some modifications. Briefly, ~1.5 × 106 cells (<= 80% confluent) each from G1AsMatSvNa (MAT1-AS)-transduced, G1xSvNa (vector)-transduced, and nontransduced (blank) cultures were collected; centrifuged at 300 × g for 5 min; washed twice with ice-cold PBS; fixed in 1% paraformaldehyde on ice for 30 min; washed twice again; and post-fixed in 70% ethanol for >= 4 h at -20 °C. The pellet was collected by centrifugation at 1000 × g for 10 min, washed twice with 2 ml of PBS, resuspended in 50 µl of FITC-dUTP staining solution, and incubated for 1 h at 37 °C. The negative control for the blank was incubated with reaction buffer lacking terminal deoxynucleotidyltransferase. Labeled cells were washed twice with PBS and stained with 1 ml of the propidium iodide/RNase solution for 30 min at 37 °C. Flow cytometric analysis was performed on a FACScalibur flow cytometer (Becton Dickinson). The cell cycle status was analyzed using ModFit LT software, and a dual parameter display for FITC-dUTP labeling was created with CellQuest Version 3.1 software (BDIS, San Jose, CA).

Assessment of Cellular and Nuclear Apoptotic Morphologies-- Apoptotic morphologic changes of cells from G1AsMatSvNa (MAT1-AS)-transduced, G1xSvNa (vector)-transduced, and nontransduced (blank) SMC cultures were determined with or without propidium iodide staining. For propidium iodide staining of nuclei, cells were grown on 8-well plastic chamber slides for 72 h to <= 80% confluence, fixed in 4% paraformaldehyde for 30 min at room temperature, permeabilized in 0.1% Triton X-100 and 0.1% sodium citrate on ice for 2 min; stained with 0.015% propidium iodide (Sigma) at room temperature for 30 min; and examined under epifluorescence illumination at ×400 magnification. The morphologic apoptotic changes of cells without propidium iodide staining were monitored under a phase-contrast microscope at ×100 magnification.

In Situ Detection of Apoptosis Using Terminal Deoxynucleotidyltransferase-mediated dUTP Nick End Labeling (TUNEL)-- In situ DNA fragmentation was detected using a TUNEL reaction kit (Boehringer Mannheim) following the manufacturer's instructions with some modifications. In brief, cells from G1AsMatSvNa (MAT1-AS)-transduced, G1xSvNa (vector)-transduced, and nontransduced (blank) cultures were grown to <= 80% confluence on 8-well chamber slides, fixed in 4% paraformaldehyde solution for 30 min at room temperature, permeabilized in 0.1% Triton X-100 and 0.1% sodium citrate for 2 min on ice, washed twice with PBS, and incubated with 50 µl of TUNEL reaction mixture in a humidified chamber for 1 h at 37 °C. Negative controls for blank, vector, and MAT1-AS cells were incubated with reaction buffer lacking terminal deoxynucleotidyltransferase. The slides were washed three time with PBS and stained with 0.015% propidium iodide for 30 min at room temperature. After a final wash with PBS, the slides were air-dried and mounted under glass coverslips with aqueous medium. The apoptotic cells in each field were examined with a Zeiss epifluorescence microscope (Axioplan/MC100) at ×400 magnification using three different filters for co-locating apoptotic nuclei: rhodamine filter (red-stained total DNA), FITC-rhodamine dual filter (yellow green-stained DNA breaks and red-stained integral DNA), and FITC filter (green-stained DNA breaks). Photomicrographs were obtained using Kodak Ektachrome Tungsten 160T film.

Analysis of DNA Fragmentation-- Low molecular weight DNA of the soluble cytoplasmic fraction was isolated as described (43-45). ~1.5 × 106 cells from G1AsMatSvNa (MAT1-AS)-transduced, G1xSvNa (vector)-transduced, and nontransduced (blank) SMC cultures were lysed in 0.5 ml of hypotonic buffer containing 10 mM Tris, pH 7.5, 1 mM EDTA, and 0.5% (v/v) Triton X-100 on ice for 30 min and centrifuged at 27,000 × g for 15 min at 4 °C. RNA in the supernatant was degraded by incubation with DNase-free RNase (50 µg/ml) at 37 °C for 1 h, followed by proteinase K digestion. DNA was precipitated with 0.1 volume of 3 M sodium acetate, pH 5.2, 20 µg/ml glycogen, and 2 volumes of anhydrous ethanol at -20 °C for 20 min. The same amount of DNA (10 µg) was electrophoresed through agarose gel, stained with ethidium bromide, and visualized under UV light. A 100-bp DNA ladder was used as a molecular size marker.

    RESULTS

MAT1 Expression Is Inhibited by RNA Antisense Sequence-- To examine whether retrovirus-mediated gene transfer of antisense MAT1 RNA inhibits endogenous MAT1 expression, the cellular MAT1 content from G1AsMatSvNa (MAT1-AS)-transduced, G1xSvNa (vector)-transduced, and nontransduced (blank) cultures was determined by Western blotting. The results show that the MAT1 content was reduced ~70% in MAT1-AS-transduced cells (Fig. 1A). To ensure that the phenotype of MAT1 expression was consistently maintained during the experimental period, MAT1 content was examined again 5 months later, after finishing all of the testing (Fig. 1B). The data confirmed that >50% decreased MAT1 expression in MAT1-AS cells was maintained during the experimental period.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 1.   MAT1 expression is inhibited by RNA antisense sequence. Aortic SMCs were either sham-transduced or transduced with G1xSvNa (vector) or G1AsMatSvNa (MAT1-AS) retroviral vectors. The MAT1 content in the transduced stable clones was determined by Western analysis. 10 µg of cell lysate proteins from stable clones as well as from nontransduced (blank) cells were separated on 16% SDS-polyacrylamide gel. The expression level of 37-kDa MAT1 protein was detected by polyclonal anti-MAT1 antibodies. The 40-kDa recombinant His-MAT1 protein (Rec.MAT1) served as a positive control. A, MAT1 expression level before the experiments; B, MAT1 content 5 months later after a series of experiments.

Abrogation of MAT1 Inhibits Aortic SMC Proliferation and Activation-- To examine whether the abrogation of MAT1 affects SMC proliferation, we used three different approaches. First, we sought to test whether abrogation of MAT1 inhibits cell duplication. This was accomplished by monitoring cell numbers over a 3-day culture period. The same number of cells from G1AsMatSvNa (MAT1-AS)-transduced, G1xSvNa (vector)-transduced, and nontransduced (blank) cultures were plated at t = 0 h and counted at 24, 48, and 72 h. The cell number from all groups declined ~20% at 24 h because of natural attachment of the cells. The data show that cell duplication was at least 50% inhibited in the MAT1-AS culture compared with the blank and vector controls (Fig. 2A).


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 2.   Abrogation of MAT1 inhibits aortic SMC proliferation. The same number of cells from G1AsMatSvNa (MAT1-AS)-transduced, G1xSvNa (vector)-transduced, and nontransduced (blank) cultures were plated for proliferation assays. A, SMC proliferation was monitored by counting the cell number up to 3 days before confluence. The growth curves represent the mean ± S.D. of cells from triplicate wells. B, subconfluent cells were incubated with MTS tetrazolium compound and quantified at 490 nm absorbance to determine the proportion of living cells in culture. The data represent the mean ± S.D. of triplicate wells.

Our second approach was to determine the proliferating cell ratio in culture. The same number of cells from G1AsMatSvNa (MAT1-AS)-transduced, G1xSvNa (vector)-transduced, and nontransduced (blank) cultures were plated and grown for 72 h for proliferation assay. The results show that the number of living cells, represented by the amount of bioreduced formazan, was reduced ~50% in the MAT1-AS culture compared with the blank and vector controls (Fig. 2B).

Arterial SMCs in vivo are normally maintained in a nonproliferative state within the tunica media. Upon arterial injury, activated SMCs migrate into the intimal layer of the arterial wall, where they proliferate and produce extracellular matrix components, which leads to neointima formation and causes angioplasty failure (25, 28, 46). Our third approach was to test whether the abrogation of MAT1 inhibits the activation of SMC proliferation from a nonproliferative state. Cells from G1AsMatSvNa (MAT1-AS)-transduced, G1xSvNa (vector)-transduced, and nontransduced (blank) cultures were grown to confluence and then scraped to release cells from contact inhibition. 24 h after the wound tracks were created, retrovirus-mediated beta -galactosidase gene transfer was performed to test the activation of SMC proliferation. Cell proliferation along the wound margin was markedly inhibited (Fig. 3A), as evidenced by the fact that only one positive X-gal-stained cell was detected in the MAT1-AS culture. Also, the closure of the wound track was significantly inhibited in the MAT1-AS cultures (Fig. 3B, MAT1-AS panel IV) compared with the blank (Blank panel IV) and vector (Vector panel IV) cultures, in which the wound tracks were completely closed at t = 60 h. In contrast, the time for closing the wound track in the MAT1-AS culture was t = 120 h (data not shown). These results show that proliferation and migration were inhibited in MAT1-AS cells by ~50%. Our data strongly suggest that MAT1 expression is required for the activation of SMC proliferation and migration from a nonproliferative state.


View larger version (104K):
[in this window]
[in a new window]
 
Fig. 3.   Abrogation of MAT1 inhibits the activation of aortic SMCs from a nonproliferative state in an in vitro injured tissue. Confluent SMCs from G1AsMatSvNa (MAT1-AS)-transduced, G1xSvNa (vector)-transduced, and nontransduced (blank) cultures were scraped to release cells from contact inhibition. A, analysis of cell activation efficiency. 24 h after the wound tracks were created, proliferation activation was tested by transduction efficiency of retroviral vector G1nBgSvNa. Activated SMC proliferation was measured at the margin of the wound track by counting the beta -galactosidase-positive cells upon exposure to X-gal under a phase-contrast microscope. B, the time for closure of the wound track. Blank panel I, Vector panel I, and MAT1-AS panel I are photographs (magnification × 40) showing that the same size wound tracks were created. Blank panel II, Vector panel II, and MAT1-AS panel II are photographs (magnification × 100) showing the appearance of the wound margin immediately upon scraping and washing to remove the detached cells. Blank panel III, Vector panel III, and MAT1-AS panel III show proliferation and migration of cells into the wound track at t = 24 h. Blank panel IV, Vector panel IV, and MAT1-AS panel IV show the closure of the wound track at t = 60 h, in which time the wound tracks in the blank and vector cells were completely closed. The time for closure of the wound track in MAT1-AS cells was t = 120 h (data not shown).

Abrogation of MAT1 Arrests Cells in G1 Phase and Triggers Apoptosis-- Since our preliminary data (data not shown) and some previous studies (20, 21) indicate that CDK7-cyclin H phosphorylation of CDKs may be MAT1-independent, we linked the cell cycle function of MAT1 using cell cycle analysis rather than testing whether the reduced MAT1 expression affects CAK-mediated phosphorylation of CDKs in these studies. Our initial studies showed that RNA antisense abrogation of MAT1 inhibited cell proliferation and activation; we sought to determine whether this inhibition was due to disruption of the normal cell cycle regulation and/or induction of apoptosis. To answer these questions, we quantified the effect of MAT1 abrogation on the cell cycle and apoptosis in relation to their position in the cell cycle. The cell cycle status and apoptosis of G1AsMatSvNa (MAT1-AS)-transduced SMCs versus controls of G1xSvNa (vector)-transduced and nontransduced (blank) SMCs were measured by flow cytometry (Fig. 4). As shown in Fig. 4 (A-C), the negative controls for blank (lacking terminal deoxynucleotidyltransferase), blank, and vector cells showed normal cell cycle profiles with 32-35% of the cells in G0/G1 phase, 39-46% in S phase, and 22-27% in G2/M phase, and the total of replicating and dividing cells was 61-73%. However, the cells from the MAT1-AS culture showed 66% of the cells in G0/G1 phase, 21% in S phase, and 13% in G2/M phase (Fig. 4D), and the total of replicating and dividing cells was 34%. Also, a peak of less than 2N DNA content falling in front of G0/G1 phase represented DNA degradation, an event reminiscent of apoptosis in the MAT1-AS culture (Fig. 4D). By comparing MAT1-AS cells with controls, the data show that in MAT1-AS cells, 1) twice as many cells were arrested in G1 phase, 2) replicating and dividing cells decreased ~50%, and 3) DNA degradation occurred during the cell cycle. We further analyzed the apoptotic cell ratio and its position in the cell cycle using the dual parameter display method (Fig. 4, E-H). The results show apoptotic cell death to be undetectable in the negative controls for blank (lacking terminal deoxynucleotidyltransferase), blank, or vector cultures (Fig. 4, E-G). In contrast, apoptotic cell death occurred ~42% of the cells in MAT1-AS cultures (Fig. 4H), and the majority of these cell deaths occurred in arrested G1 cells. These results strongly suggest that MAT1 is required for G1 exit and that apoptosis is triggered by G1 arrest.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 4.   Abrogation of MAT1 arrests cells in G1 phase and induces apoptosis. Nuclei of cells from G1AsMatSvNa (MAT1-AS)-transduced, G1xSvNa (vector)-transduced, and nontransduced (blank) cells were analyzed for DNA content and DNA breaks by flow cytometry. The estimated proportion of G0/G1 phase cells in the negative control for blank (lacking terminal deoxynucleotidyltransferase), blank, and vector cultures (A-C, respectively) ranged from 32 to 35%. In contrast, 66% of the MAT1-AS cells were in G0/G1 phase (D). DNA breaks were not detectable in the blank and vector cultures (F and G, respectively). An estimated 42% DNA breaks occurred in the MAT1-AS cells, and the majority of DNA breaks consisted of arrested G1 phase cells (H).

Apoptotic Morphologic Criteria in Cells Transduced with Antisense MAT1 RNA-- G1AsMatSvNa (MAT1-AS)-transduced cells not only showed inhibited cell proliferation, but also had a visible apoptotic morphology (Fig. 5). The cells became rounded and developed vesiculations around the cell borders (Fig. 5C) compared with nontransduced (blank) and G1xSvNa (vector)-transduced cells (Fig. 5, A and B). We also used the propidium iodide stain to analyze the apoptotic morphologic changes in the nuclei of the cells. Under an epifluorescence microscope, we found condensation of nuclear chromatin and nuclear fragmentation in MAT1-AS cells (Fig. 5F). Similar apoptotic changes were undetectable in blank and vector cultures (Fig. 5, D and E). These results show that the retarded SMC proliferation is associated with apoptosis.


View larger version (70K):
[in this window]
[in a new window]
 
Fig. 5.   Apoptotic changes of cellular and nuclear morphologies. Cells from G1AsMatSvNa (MAT1-AS)-transduced, G1xSvNa (vector)-transduced, and nontransduced (blank) cultures were photographed for cellular and nuclear morphologies. A-C were photographed under a phase-contrast microscope. MAT1-AS cells (C) displayed cell shrinkage, the blebbing of plasma membranes, nuclear condensation, and nuclear fragmentation. The blank (A) and vector (B) cultures showed normal cell morphology. D-F are propidium iodide-stained nuclei and were photographed under an epifluorescence microscope. MAT1-AS cells (F) showed condensation of nuclear chromatin and nuclear fragmentation, whereas the blank (D) and vector (E) cultures showed normal nuclei.

Detection of Apoptotic Cell Death-- The biochemical hallmark of apoptosis is the cleavage of chromosomal DNA into oligonucleosomal units (47-49). To characterize this cell death process, the TUNEL assay was used to detect in situ apoptotic cell death. As shown in Fig. 6, the nuclear fragmentation was easily identified by co-locating apoptotic nuclei of G1AsMatSvNa (MAT1-AS)-transduced cells under an epifluorescence microscope using three different filters (Fig. 6, C, F, and I), and this was not seen in either the blank (Fig. 6, A, D, and G) or vector (Fig. 6, B, E, and H) culture. We also used an alternative method, agarose gel electrophoresis, to detect DNA fragmentation (Fig. 7). The low molecular weight DNA of the soluble cytoplasmic fraction isolated from G1AsMatSvNa (MAT1-AS)-transduced cells displayed a characteristic oligonucleosomal fragmentation ~200 bp in length, which was undetectable in nontransduced (blank) and G1xSvNa (vector)-transduced cells.


View larger version (66K):
[in this window]
[in a new window]
 
Fig. 6.   In situ detection of apoptotic cell death. Cells from G1AsMatSvNa (MAT1-AS)-transduced, G1xSvNa (vector)-transduced, and nontransduced (blank) cultures were analyzed in situ for apoptosis using the TUNEL assay. DNA breaks of cells were labeled with FITC-dUTP, followed by counterstaining with propidium iodide. The nuclei of cells were co-located under an epifluorescence microscopy using three different filters: red for total DNA stain (A-C), yellow green for apoptotic nuclei stain and red for integral DNA stain (D-F), and green for apoptotic nuclei stain (G-I). The apoptotic nuclei were identified in the MAT1-AS culture (C, F, and I) (arrowhead; bar = 30 µm), but were undetectable in the blank (A, D, and G) and vector (B, E, and H) cells. Negative controls for blank, vector, and MAT1-AS cells were incubated with reaction buffer lacking terminal deoxynucleotidyltransferase (data not shown).


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 7.   Analysis of oligonucleosomal fragmentation. Lanes 2-4 contain 10 µg of low molecular weight DNA isolated from nontransduced (blank), G1xSvNa (vector)-transduced, and G1AsMatSvNa (MAT1-AS)-transduced cells. Lane 1 contains molecular size markers.


    DISCUSSION

Cell cycle transitions are processes that are highly regulated by ordered assembly and timing-activated CDK complexes, and inhibition of these kinases will cause cell cycle arrest (35, 36). CAK regulates cell cycle progression by activating CDK complexes through phosphorylation of a critical threonine residue in their T-loop domain (50, 51), whereas MAT1 functions in the cell cycle by stabilizing the association of CDK7 with cyclin H (1, 4, 6) and determining substrate specificity of CDK7-cyclin H (20, 21, 23). In contrast to the detailed mechanisms of regulatory subunit cyclins and catalytic subunit CDKs, whose functions have been relatively defined in a certain period of the cell cycle, little is known about the cell cycle phase specificity of the targeting subunit MAT1 in cell cycle regulation. In this study, we have shown that abrogation of MAT1 arrests SMCs in G1 phase, triggers apoptosis, and retards SMC proliferation. Thus, our data suggest a novel mechanism by which MAT1 controls cell proliferation through regulating the G1 exit and mediating apoptosis.

MAT1 Regulates G1 Exit to Control Cell Proliferation-- G1, S, G2, and M phases are major cell cycle states. Identifying the factors that trigger the transitions between cell cycle phases is one of the major goals in cell cycle research (35, 36, 50-53). In our studies using RNA antisense abrogation of MAT1, we found that the proportion of G1 phase cells is doubled and that cells in S and M phases decrease 50% (Fig. 4D) compared with controls (Fig. 4, A-C). These data, showing that abrogation of MAT1 causes G1 arrest, reduces proliferating cells, and induces DNA degradation (Fig. 4, A-D), are consistent with the results of cell proliferation assays. For example, SMC proliferation is decreased ~50% in antisense MAT1-transduced cells (Fig. 2); SMC proliferation efficiency from a nonproliferative to proliferative state is inhibited at least 50% (Fig. 3). It is known that cell cycle transition through the G1 restriction point and entry into S phase are controlled by the activities of CDK complexes (35, 36, 51). Our results strongly suggest that abrogation of MAT1 may cause failure of assembly and/or determination of substrate specificity of CAK or other CDK complexes at the G1 exit, so that the cells are arrested in G1 phase. Currently, a CDK4-cyclin D complex has been depicted downstream of CAK (11, 12, 16). The CDK4-cyclin D complex phosphorylates and inactivates pRb for G1 exit (54, 55). A loss of cyclin D-dependent kinase activity prevents many cultured cell lines from entering S phase (56), whereas overexpression of cyclin D shortens the G1 phase (57). Besides the CDK4-cyclin D complex, CDK2-cyclin E and CDK2-cyclin A complexes are also involved in G1/S transition (58, 59). Given that a loss of MAT1 causes G1 phase arrest, our data support the view that MAT1 functions in G1 exit to control G1/S transition. The challenging question that awaits to be answered is how the G1 exit is regulated by MAT1: (a) by determining substrate specificity of CAK at G1/S transition through directly interacting with those known CDK complexes of G1/S transition, e.g. cyclin D-, A-, or E-associated CDK complexes; (b) by regulating other CDK complex assembly and interaction; or (c) by modification of substrate specificity before the restriction point or at G1/S transition, e.g. whether pRb or p53 is one such target.

Abrogation of MAT1 Triggers Apoptosis-- Apoptosis removes damaged, virus-infected, and unwanted cells for (i) development and homeostasis, (ii) defense, and (iii) aging (60-62). Under normal circumstances, if any damage or block is irreparable, most cells initiate a sequence of biochemical events leading to programmed cell death or apoptosis (63). In our studies, apoptotic cell death was induced by G1 phase arrest (Fig. 4D), and the majority of apoptosis occurred in the arrested G1 cells (Fig. 4H). Our data also show that the retarded cell proliferation (Figs. 2 and 3) is the consequent incident following G1 phase arrest and apoptotic cell death. Control of cell number is determined by an intricate balance of cell death and cell proliferation. Our data not only demonstrate that the inhibited SMC proliferation was due to G1 arrest and apoptosis, but also indicate a link between cell cycle control mechanisms and apoptosis. A recent report that an antitumor agent, Noscapine, arrests cells at mitosis and induces apoptosis is an example that apoptosis machinery responds to disregulated cell cycle events and kills dividing cells (45). Some cell cycle components, e.g. p34CDC2-, cyclin B-, and cyclin A-associated CDKs, may participate, directly or indirectly, in part of the apoptotic pathway under certain conditions (64-67). Our results, together with other studies, support the view that the MAT1 gene, as a G1 exit factor to trigger G1/S transition, may also act as an upstream regulator of apoptosis machinery for homeostatic balance of cell population. Determining how the abrogation of MAT1 causes G1 phase arrest and induces apoptosis may elucidate the mechanisms that link cell cycle control with apoptosis and allow the design of therapies that prevent cells from replication and that enhance cell death in the treatment of luminal narrowing in vascular occlusive diseases and proliferation disorders in cancer.

    FOOTNOTES

* This work was supported by a Research Career Development award (to L. W.) from the Childrens Hospital Los Angeles/University of Southern California School of Medicine.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed: Childrens Hospital Los Angeles Research Inst./University of Southern California School of Medicine, Smith Research Tower, MS 103, 4650 Sunset Blvd., Los Angeles, CA 90027. Tel.: 323-660-2450 (ext. 6318); Fax: 323-666-0489; E-mail: lingtaow{at}hsc.usc.edu.

    ABBREVIATIONS

The abbreviations used are: CDK, cyclin-dependent kinase; CAK, CDK-activating kinase; TFIIH, transcription factor IIH; SMC, smooth muscle cell; bp, base pair(s); X-gal, 5-bromo-4-chloro-3-indolyl beta -D-galactopyranoside; PBS, phosphate-buffered saline; FITC, fluorescein isothiocyanate; TUNEL, terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling; MTS, (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy methoxyphenyl)-2-(4-sulfophenyl)-24-tetrazolium.

    REFERENCES
Top
Abstract
Introduction
References
  1. Tassan, J. P., Jaquenoud, M., Fry, A. M., Frutiger, S., Hughes, G. J., and Nigg, E. A. (1995) EMBO J. 14, 5608-5617[Abstract]
  2. Yee, A., Nichols, M. A., Wu, L., Hall, F. L., Kobayashi, R., and Xiong, Y. (1995) Cancer Res. 55, 6058-6062[Abstract]
  3. Yee, A., Wu, L., Liu, L., Kobayashi, R., Xiong, Y., and Hall, F. L. (1996) J. Biol. Chem. 271, 471-477[Abstract/Free Full Text]
  4. Fisher, R. P., Jin, P., Chamberlin, H. M., and Morgan, D. O. (1995) Cell 83, 47-57[Medline] [Order article via Infotrieve]
  5. Martinez, A. M., Afshar, F. M., Cavadore, J. C., Labbé, J. C., and Doreé, M. (1997) EMBO J. 16, 343-354[Abstract/Free Full Text]
  6. Devault, A., Martinez, A. M., Fesquet, D., Labbé, J. C., Morin, N., Tassan, J. P., Nigg, E. A., Cavadore, J. C., and Dorée, M. (1995) EMBO J. 14, 5027-5036[Abstract]
  7. Roy, R., Adamczewski, J. P., Seroz, T., Vermeulen, W., Tassan, J. P., Schaeffer, L., Nigg, E. A., Hoeijmakers, J. H. J., and Egly, J. M. (1994) Cell 79, 1093-1101[Medline] [Order article via Infotrieve]
  8. Serizawa, H., Makela, T. P., Conaway, J. W., Conaway, R. C., Weinberg, R. A., and Young, R. A. (1995) Nature 374, 280-282[CrossRef][Medline] [Order article via Infotrieve]
  9. Shiekhattar, R., Mermlstein, F., Fisher, R., Drapkin, R., Dynlacht, B., Wessling, H. C., and Reinbert, D. (1995) Nature 374, 283-287[CrossRef][Medline] [Order article via Infotrieve]
  10. Reardon, J. T., Ge, H., Gibbs, E., Sancar, A., Hurwitz, J., and Pan, Z. Q. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 6482-6487[Abstract/Free Full Text]
  11. Fesquet, D., Labbé, J. C., Derancourt, J., Capony, J. P., Galas, S., Girard, F., Lorca, T., Shuttleworth, J., Dorée, M., and Cavadore, J. C. (1993) EMBO J. 12, 3111-3121[Abstract]
  12. Poon, R. Y., Yamashita, K., Adamczewski, J. P., Hunt, T., and Shuttleworth, J. (1993) EMBO J. 12, 3123-3132[Abstract]
  13. Poon, R. Y., Yamashita, K., Howell, M., Ershler, M. A., Belyavsky, A., and Hunt, T. (1994) J. Cell Sci. 107, 2789-2799[Abstract/Free Full Text]
  14. Solomon, M. J., Harper, J. M., and Shuttleworth, J. (1993) EMBO J. 12, 3133-3142[Abstract]
  15. Fisher, R. P., and Morgan, D. O. (1994) Cell 78, 713-724[Medline] [Order article via Infotrieve]
  16. Nigg, E. A. (1996) Curr. Opin. Cell Biol. 8, 312-317[CrossRef][Medline] [Order article via Infotrieve]
  17. Chalut, C., Moncollin, V., and Egly, J. M. (1994) Bioassays 16, 651-655[Medline] [Order article via Infotrieve]
  18. Goodrich, J. A., and Tjian, R. (1994) Cell 74, 145-156
  19. Drapkin, R., and Reinberg, D. (1994) Trends Biochem. Sci. 19, 504-508[CrossRef][Medline] [Order article via Infotrieve]
  20. Yankulov, K. Y., and Bentley, D. L. (1997) EMBO J. 16, 1638-1646[Abstract/Free Full Text]
  21. Ko, L. J., Shieh, S. Y., Chen, X., Jayaraman, L., Tamai, K., Tay, A. Y., Prives, C., and Pan, Z. Q. (1997) Mol. Cell. Biol. 17, 7220-7229[Abstract]
  22. Drapkin, R., Roy, G. L., Cho, H., Akoulitchev, S., and Reinberg, D. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 6488-6493[Abstract/Free Full Text]
  23. Rossignol, M., Isabelle, K. C., and Egly, J. M. (1997) EMBO J. 10, 1628-1637[CrossRef]
  24. Miano, J. M., Vlasic, N., Tota, R. R., and Stemerman, M. B. (1993) Arterioscler. Thromb. 13, 211-219[Abstract]
  25. Raines, E. W., and Ross, R. (1993) Br. Heart J. 69, S30-S37[Medline] [Order article via Infotrieve]
  26. Rekhter, M., Nicholls, S., Ferguson, M., and Gordon, D. (1993) Arterioscler. Thromb. 13, 609-617[Abstract]
  27. Geary, R. L., Williams, J. K., Golden, D., Brown, D. G., Benjamin, M. E., and Adams, M. R. (1996) Arterioscler. Thromb. Vasc. Biol. 16, 34-43[Abstract/Free Full Text]
  28. Gibbons, G. H., and Dzau, V. J. (1996) Science 272, 689-693[Abstract]
  29. Smith, R. C., Wills, K. N., Antelman, H., Truong, L. N., Krasinski, K., and Walsh, K. (1997) Circulation 96, 1899-1905[Abstract/Free Full Text]
  30. Billingham, M. E. (1997) Clin. Transplant. 8, 289-292
  31. Yamada, T., Itoh, T., Nakano, S., and Tokunga, O. (1997) Heart Vessels 10, 41-45
  32. Morishita, R., Gibbons, G. H., Ellison, K. E., Nakajima, M., and Zhang, L. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 8474-8478[Abstract/Free Full Text]
  33. Chang, M. W., Barr, E., Seltzer, J., Jiang, Y. Q., Nabel, G. J., Nabel, E. G., Parmacek, M. S., and Leiden, J. M. (1995) Science 267, 518-522[Medline] [Order article via Infotrieve]
  34. Yang, Z., Simari, R. D., Perkins, N. D., San, H., Gordon, D., Nabel, G., and Nabel, E. G. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 7905-7910[Abstract/Free Full Text]
  35. Nasmyth, K. (1996) Science 274, 1643-1645[Free Full Text]
  36. Elledge, S. J. (1996) Science 274, 1664-1672[Abstract/Free Full Text]
  37. Wu, L., Yee, A., Liu, L., Carbonaro-Hall, D., Venatesan, N., Tolo, V. T., and Hall, F. (1994) Oncogene 9, 2089-2096[Medline] [Order article via Infotrieve]
  38. Wu, L., Liu, L., Yee, A., Carbonaro-Hall, D., Tolo, V., and Hall, F. (1994) Oncol. Rep. 1, 705-711
  39. Hwang, J. J., Scuric, Z., and Anderson, W. F. (1996) J. Virol. 70, 8138-8141[Abstract]
  40. Wu, L., Williams, R., Carbonaro-Hall, D., Liu, L., Tolo, V., and Hall, F. L. (1993) Int. J. Oncol. 3, 859-867
  41. Zhu, N. L., Wu, L., Liu, P. X., Gordon, E. M., Anderson, W. F., Starnes, V. A., and Hall, F. L. (1997) Circulation 96, 628-635[Abstract/Free Full Text]
  42. Gorczyca, W., Gong, J., Ardelt, B., Traganos, F., and Darzynkiewicz, Z. (1993) Cancer Res. 53, 3186-3192[Abstract]
  43. Yasuda, T., Grinspan, J., Stern, J., Franceschini, B., Bannerman, P., and Pleasure, D. (1995) J. Neurosci. Res. 40, 306-317[Medline] [Order article via Infotrieve]
  44. Fox, J. C., and Shanley, J. R. (1996) J. Biol. Chem. 271, 12578-12584[Abstract/Free Full Text]
  45. Ye, K., Ke, Y., Keshava, N., Shanks, J., Kapp, J. A., Tekmal, R. R., Petros, J., and Joshi, H. C. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 1601-1606[Abstract/Free Full Text]
  46. Schwartz, S. M., deBlois, D., and O'Brien, E. R. (1995) Circ. Res. 77, 445-465[Free Full Text]
  47. Wyllie, A. H. (1980) Nature 284, 555-556[Medline] [Order article via Infotrieve]
  48. Wyllie, A. H., Morris, R. G., Smith, A. L., and Dunlop, D. (1984) J. Pathol. 142, 66-77
  49. Compton, M. M. (1992) Cancer Metastasis Res. 11, 105-119[Medline] [Order article via Infotrieve]
  50. Sherr, C. J. (1994) Cell 79, 551-555[Medline] [Order article via Infotrieve]
  51. Morgan, D. O. (1995) Nature 374, 131-134[CrossRef][Medline] [Order article via Infotrieve]
  52. Sherr, C. J. (1993) Cell 73, 1059-1065[Medline] [Order article via Infotrieve]
  53. Hunter, T., and Pines, J. (1994) Cell 79, 573-582[Medline] [Order article via Infotrieve]
  54. Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J., and Livingston, D. M. (1993) Cell 73, 487-497[Medline] [Order article via Infotrieve]
  55. Kato, J., Matsushime, H., Hiebert, S. W., Ewen, M. E., and Sherr, C. J. (1993) Genes Dev. 7, 331-342[Abstract]
  56. Baldin, V., Lukas, J., Marcote, M. J., Pagano, M., and Draetta, G. (1993) Genes Dev. 7, 812-821[Abstract]
  57. Quelle, D., Ashmun, R., Shurtleff, S., Kato, J., Bar-segi, D., Roussel, M., and Sherr, C. (1993) Genes Dev. 7, 1559-1571[Abstract]
  58. Sherr, C. J. (1996) Science 274, 1672-1677[Abstract/Free Full Text]
  59. Ohtsubo, M., Theodoras, A. M., Schumather, J., Roberts, J. M., and Pagano, M. (1995) Mol. Cell. Biol. 15, 2612-2624[Abstract]
  60. Vaux, D. L., and Strasser, A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 2239-2244[Abstract/Free Full Text]
  61. Jacobson, M. D., Weil, M., and Raff, M. C. (1997) Cell 88, 347-354[Medline] [Order article via Infotrieve]
  62. Peter, M. E., Heufelder, A. E., and Henggartner, M. O. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 12736-12737[Abstract/Free Full Text]
  63. White, E. (1996) Genes Dev. 10, 1-5[CrossRef][Medline] [Order article via Infotrieve]
  64. Shi, L., Nishioka, W. K., Th'ng, J., Bradbury, E. M., Litchfield, D. W., and Greenberg, A. H. (1994) Science 263, 1143-1145[Medline] [Order article via Infotrieve]
  65. Fotedar, R., Flatt, J., Gupta, S., Margolis, R. L., Fitzgerald, P., Messier, H., and Fotedar, A. (1995) Mol. Cell. Biol. 15, 932-942[Abstract]
  66. Krek, W., and Nigg, E. A. (1991) EMBO J. 10, 3331-3341[Abstract]
  67. Li, C. J., Friedman, D. J., Wang, C., Metelev, V., and Pardee, A. B. (1995) Science 268, 429-431[Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.